In 2013, the Food and Drug Administration (FDA) approved mipomersen as an adjunct to lipid-lowering therapy and dietary modifications to lower LDL-C, ApoB, and non-HDL-C in patients diagnosed with homozygous familial hypercholesterolemia (HoFH) [183]. This evidence concerns the gene APOB and familial hypercholesterolemia.